Comparison of vitamin D levels in obese and non obese patients with polycystic ovarian syndrome in a South Indian population
Keywords:
Polycystic ovary syndrome, Insulin resistance, Obese, Vitamin DAbstract
Polycystic ovary syndrome (PCOS) is the most common metabolic abnormality occurring in young women of reproductive age. Low vitamin D levels were found to be associated with the development of obesity and insulin resistance in young women with PCOS. The study was conducted as a prospective observational study involving 121 women with PCOS. The diagnosis of PCOS cases were based on the revised Rotterdam consensus criteria. Vitamin D levels were compared in the obese and non obese PCOS groups and also with the controls. In the PCOS group, sixty subjects were obese with BMI of ≥25 kg/m2 and forty seven subjects were found to be non obese. In the control group, sixteen subjects were obese and sixty five subjects were non obese. The mean vitamin D level in the PCOS group was 15.45±7.88 ng/ml and in the control group was 12.83±5.76ng/ml. The mean vitamin D levels in the obese and non obese group with PCOS were 16.11±8.9ng/ml and 14.61±6.1ng/ml respectively. Majority of the patients and controls had vitamin D deficiency and there was no difference in the vitamin D levels in PCOS group and controls as well as obese and non obese groups.
Metrics
References
Azziz R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89(6):2745-9.
Hart, R., M. Hickey, and S. Franks, Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol, 2004. 18(5): p. 671-83.
Rotterdam, E.A.-S.P.c.w.g., Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. 19(1): p. 41-7.
Azziz, R., et al., The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril, 2009. 91(2): p. 456-88.
Holick, M.F., Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am, 2010. 39(2): p. 381-400, table of contents.
Holick, M.F., Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr, 2004. 80(6 Suppl): p. 1678S-88S.
Hahn, S., et al., Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes, 2006. 114(10): p. 577-83.
Yildizhan, R., et al., Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet, 2009. 280(4): p. 559-63.
Zawadzki, J., Dunaif, A. , Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach.In: Polycystic Ovary Syndrome, Dunaif,A, Givens,JR,Haseltine,FP,Merriam,GE(Eds), Current Issues in Endocrinology and Metabolism,Blackwell Scientific Publications,Boston. 1992: p. 377
Johnstone, E.B., et al., The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab, 2010. 95(11): p. 4965-72.
Rotterdam, E.A.-S.P.C.W.G., Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 2004. 81(1): p. 19-25.
Azziz, R., et al., Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab, 2006. 91(11): p. 4237-45.
Gluckman, P.D., et al., Effect of in utero and early-life conditions on adult health and disease. N Engl J Med, 2008. 359(1): p. 61-73.
Rosenfield, R.L., Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab, 2007. 92(3): p. 787-96.
Franks, S., J. Stark, and K. Hardy, Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update, 2008. 14(4): p. 367-78.
Yang, G.R., et al., Neck circumference positively related with central obesity, overweight, and metabolic syndrome in Chinese subjects with type 2 diabetes: Beijing Community Diabetes Study 4. Diabetes Care, 2010. 33(11): p. 2465-7.
Hollis, B.W., Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Endocrinol Metab Clin North Am, 2010. 39(2): p. 271-86, table of contents.
Prosser, D.E. and G. Jones, Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci, 2004. 29(12): p. 664-73.
Moan, J., et al., Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci U S A, 2008. 105(2): p. 668-73.
Tangpricha, V., et al., Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health. Am J Clin Nutr, 2003. 77(6): p. 1478-83.
Colston, K., M.J. Colston, and D. Feldman, 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology, 1981. 108(3): p. 1083-6.
Schwartz, G.G., et al., Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev, 1998. 7(5): p. 391-5.
Holick, M.F., Vitamin D deficiency. N Engl J Med, 2007. 357(3): p. 266-81.
Grant, W.B. and M.F. Holick, Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev, 2005. 10(2): p. 94-111.
Holick, M.F., et al., Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2011. 96(7): p. 1911-30.
Holick, M.F., et al., Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab, 2008. 93(3): p. 677-81.
Heaney, R.P., et al., Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr, 2003. 77(1): p. 204-10.
Kim, M.K., et al., The association of serum vitamin D level with presence of metabolic syndrome and hypertension in middle-aged Korean subjects. Clin Endocrinol (Oxf), 2010. 73(3): p. 330-8.
Forouhi, N.G., et al., Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes, 2008. 57(10): p. 2619-25.
Lu, L., et al., Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care, 2009. 32(7): p. 1278-83.
Gagnon, C., et al., Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab, 2012. 97(6): p. 1953-61.
Harinarayan, C.V., Prevalence of vitamin D insufficiency in postmenopausal south Indian women. Osteoporos Int, 2005. 16(4): p. 397-402.
Marwaha, R.K. and G. Sripathy, Vitamin D & bone mineral density of healthy school children in northern India. Indian J Med Res, 2008. 127(3): p. 239-44.
Harinarayan, C.V., et al., Vitamin D status and bone mineral density in women of reproductive and postmenopausal age groups: a cross-sectional study from south India. J Assoc Physicians India, 2011. 59: p. 698-704.
Wehr, E., et al., Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol, 2009. 161(4): p. 575-82.
Wehr, E., T.R. Pieber, and B. Obermayer-Pietsch, Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest, 2011. 34(10): p. 757-63.
Mahmoudi, T., Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertil Steril, 2009. 92(4): p. 1381-3.
Ranjzad, F., et al., Influence of gene variants related to calcium homeostasis on biochemical parameters of women with polycystic ovary syndrome. J Assist Reprod Genet, 2011. 28(3): p. 225-32.
Wehr, E., et al., Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol, 2011. 164(5): p. 741-9.
Panidis, D., et al., Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem, 2005. 51(9): p. 1691-7.
Thys-Jacobs, S., et al., Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids, 1999. 64(6): p. 430-5.
Li, H.W., et al., Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism, 2011. 60(10): p. 1475-81.
Savastano, S., et al., Serum 25-Hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS. Nutr Metab (Lond), 2011. 8: p. 84.
Ardabili, H.R., B.P. Gargari, and L. Farzadi, Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res, 2012. 32(3): p. 195-201.
Nishida, C., G.T. Ko, and S. Kumanyika, Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist-Hip Ratio. Eur J Clin Nutr, 2010. 64(1): p. 2-5.
Misra, A., et al., Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009;57:163-70.
